HC Wainwright & Co. Maintains Buy on BioNTech, Raises Price Target to $150
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained a Buy rating on BioNTech and raised its price target from $113 to $150, indicating a positive outlook for the company's stock.
October 07, 2024 | 10:42 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has maintained a Buy rating on BioNTech and increased the price target from $113 to $150, suggesting confidence in the company's future performance.
The increase in the price target from $113 to $150 by HC Wainwright & Co. reflects a strong positive sentiment towards BioNTech's future performance. This is likely to lead to a short-term increase in the stock price as investors react to the updated target and maintained Buy rating.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100